Updated
Reviewed by Vidhi Upadhyay
Africa Cell Therapy Manufacturing Market Industry Trends and Forecast to 2034: Segmented by (Product, Cell Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$248.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $58.7 Mn | — | — |
| 2025 (base) | $69.5 Mn | +$10.8 Mn | — |
| 2026 (forecast) | $82.3 Mn | +$12.8 Mn | +18.4% |
| 2027 (forecast) | $97.5 Mn | +$15.1 Mn | +40.2% |
| 2028 (forecast) | $115.4 Mn | +$17.9 Mn | +66% |
| 2029 (forecast) | $136.6 Mn | +$21.2 Mn | +96.5% |
| 2030 (forecast) | $161.8 Mn | +$25.1 Mn | +132.7% |
| 2031 (forecast) | $191.6 Mn | +$29.8 Mn | +175.5% |
| 2032 (forecast) | $226.8 Mn | +$35.2 Mn | +226.2% |
| 2033 (forecast) | $268.5 Mn | +$41.7 Mn | +286.2% |
| 2034 (forecast) | $317.9 Mn | +$49.4 Mn | +357.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.70 Bn
Canada
$392.5 Mn
China
$389.4 Mn
Japan
$287.7 Mn
Germany
$189.8 Mn
France
$136.4 Mn
Italy
$119.7 Mn
Brazil
$118.3 Mn
UK
$111.1 Mn
Ecuador
$107.5 Mn
India
$102.0 Mn
Spain
$85.7 Mn
Saudi Arabia
$86.6 Mn
Mexico
$62.9 Mn
Australia
$60.2 Mn
Russia
$54.0 Mn
New Zealand
$47.8 Mn
South Africa
$27.9 Mn
UAE
$26.0 Mn
Egypt
$14.7 Mn
Philippines
$11.3 Mn
Malaysia
$8.0 Mn
Hong Kong
$6.6 Mn
Thailand
$5.4 Mn
Singapore
$5.0 Mn
Kenya
$3.8 Mn
| Market size, 2025 | $69.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $317.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, cell type and end user (see all) |
| Key players | Lonza Ltd, Thermo Fisher Scientific Inc., Cytiva (Danaher), Miltenyi Biotec, Charles River Laboratories and 1 more (see all) |
| Regulator in Africa | AMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026. |
| Active clinical trials | 1 in AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Cell therapy manufacturing covers the equipment, materials and services used to grow, change and package living cells for treatment.
Key segments of the cell Therapy Manufacturing market include product (Consumables, Equipment and Services) and cell type (T Cells, Stem Cells and NK Cells).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell Therapy Manufacturing market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the cell Therapy Manufacturing market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the cell Therapy Manufacturing market. Payers are still working out how to pay for one-time cures.
The cell Therapy Manufacturing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)[2], PPB (Kenya)[3] and SAHPRA (South Africa)[4]. How care is paid for in some of these countries: universal health insurance (Egypt)[5], the SHA (Kenya)[6] and planned National Health Insurance (South Africa)[7]. ClinicalTrials.gov lists 1 study on Cell Therapy Manufacturing that is recruiting, active or about to start in Africa.[8]
[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
[2] Egyptian Drug Authority. Checked 14 Nov 2026.
[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.
[5] Universal Health Insurance Authority. Checked 14 Nov 2026.
[6] Social Health Authority. Checked 14 Nov 2026.
[7] National Department of Health. Checked 14 Nov 2026.
[8] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Africa. Retrieved 12 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cell Therapy Manufacturing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.
What doctors and scientists are doing in Cell Therapy Manufacturing right now, from free public sources.
1 active trial in Egypt, South Africa, Kenya, Nigeria, Ethiopia, DR Congo, Uganda, Tanzania, Niger, Mozambique, Sudan, Malawi, Zambia, Mali, Burkina Faso, Ghana and Morocco
Recruiting, about to start, or running now. Counted across the 17 countries we report on in Africa.
See every trial on ClinicalTrials.gov (opens in a new tab)Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Africa · 3 shared keywords
Africa · 2 shared keywords
Africa · 2 shared keywords
Africa · 1 shared keyword
Africa · 1 shared keyword
Africa · 1 shared keyword
Healthcare Services · Africa
Healthcare Services · Africa
Healthcare Services · Africa
Healthcare Services · Africa
Healthcare Services · Africa
Healthcare Services · Africa
